CD274 and neoplasm: To provide a more solid approach, a staining panel combining three different anti-PD-L1 Ab (SP142, 22C3 and SP263) together with tumor and immune markers, like EpCAM and CD45, respectively, is currently being used to allow a better characterization of PD-L1 expression within the tumor and possibly a better stratification for the iCPI therapy.